(Q45051203)

8 December 2017

Risk factors for male lower urinary tract symptoms: the role of metabolic syndrome and androgenetic alopecia in a Latin American population (English)

1 reference

8 December 2017

1 reference

1 reference

João Arthur B A Barbosa

1

1 reference

8 December 2017

Eduardo Muracca

2

1 reference

8 December 2017

Elcio Nakano

3

1 reference

8 December 2017

Mário Paranhos

4

1 reference

8 December 2017

Renato Natalino

5

1 reference

8 December 2017

Paulo Cordeiro

6

1 reference

8 December 2017

Miguel Srougi

7

1 reference

8 December 2017

Alberto Azoubel Antunes

8

1 reference

8 December 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

8 December 2017

1 reference

8 December 2017

82

1 reference

8 December 2017

1

1 reference

8 December 2017

182-188

1 reference

Steroid hormones and hormone-related genetic and lifestyle characteristics as risk factors for benign prostatic hyperplasia: review of epidemiologic literature

8 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Do atherosclerosis and chronic bladder ischemia really play a role in detrusor dysfunction of old age?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Are lower urinary tract symptoms influenced by metabolic syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Role of genetics and sex steroid hormones in male androgenetic alopecia and female pattern hair loss: an update of what we now know

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Association of androgenetic alopecia with metabolic syndrome in men: a community-based survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Androgenetic alopecia and cardiovascular risk factors in men and women: a comparative study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Finasteride, 1 mg daily administration on male androgenetic alopecia in different age groups: 10-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (Com

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Androgenetic alopecia as an early marker of benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Association of benign prostatic hyperplasia with male pattern baldness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Baldness, benign prostate hyperplasia, prostate cancer and androgen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Patients with a large prostate show a higher prevalence of androgenetic alopecia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Selective nitrergic neurodegeneration in diabetes mellitus - a nitric oxide-dependent phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Ethnicity and migration as determinants of human prostate size

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

5alpha-reductase isozymes and androgen actions in the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

Reliability of hamilton-norwood classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.001

10.1016/J.UROLOGY.2013.03.001

7 January 2021

Identifiers

DOI

1 reference

8 December 2017

1 reference